His time at the helm was also marked by a major cyberattack that compromised the data of 190 million people, as well as ...

Under the agreement, GSK will acquire BP Asset IX, a subsidiary of Boston Pharmaceuticals, for up to $2 billion in total cash ...

Lockheed Martin lays off 64 Mass. clean energy workers Lockheed Martin lays off 64 Mass. clean energy workers © 2025 American ...

The new acquisition from Boston Pharmaceuticals adds to a wave of dealmaking undertaken by GSK to build its liver disease ...

British pharmaceutical giant GlaxoSmithKline announced Wednesday the acquisition of a drug under development to treat a ...

GSK will buy efimosfermin, a liver disease drug in late-stage trials, for up to $2 billion from U.S. biotechnology firm ...

Global biopharmaceutical leader GSK PLC has entered into a definitive agreement to acquire efimosfermin, a promising ...

GSK acquires Boston Pharmaceuticals' efimosfermin for up to $2 billion, targeting liver diseases like MASH and ALD.

Belrestotug showed underwhelming efficacy outcomes in mid-stage studies of non-small cell lung cancer and head and neck ...

GSK is acquiring an experimental medicine from a Cambridge biotech to shore up its drug pipeline and muscle into the ...

Just a day after dropping a $625m cancer asset, GSK has inked a deal worth a potential $2bn to acquire Boston Pharmaceuticals ...

GSK has agreed to pay $1.2 billion upfront to acquire rights to efimosfermin from Cambridge, Massachusetts-based Boston ...